Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis

Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis

Hepatocellular carcinoma (HCC) with coexisting portal vein tumor thrombus (PVTT) is associated with poor patient outcomes. The efficacy and safety of neoadjuvant therapy in patients with HCC with PVTT remain a subject of debate. In the present study, a comprehensive search of electronic databases, i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology letters 2025-03, Vol.29 (3), p.122, Article 122
Hauptverfasser: Xuan, Wangyi, Zhang, Xiaoming, Fang, Yingying, Zhang, Yueming, Xiang, Zhiyi, Yu, Yifei, Wu, Qingping, Zhang, Xingfen
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page 122
container_title Oncology letters
container_volume 29
creator Xuan, Wangyi
Zhang, Xiaoming
Fang, Yingying
Zhang, Yueming
Xiang, Zhiyi
Yu, Yifei
Wu, Qingping
Zhang, Xingfen
description Hepatocellular carcinoma (HCC) with coexisting portal vein tumor thrombus (PVTT) is associated with poor patient outcomes. The efficacy and safety of neoadjuvant therapy in patients with HCC with PVTT remain a subject of debate. In the present study, a comprehensive search of electronic databases, including PubMed, Web of Science, Embase and the Cochrane Library, was conducted to identify studies evaluating the outcomes of neoadjuvant therapy in patients with HCC and PVTT. The primary outcomes assessed were overall survival (OS) and relapse-free survival (RFS), with complication rates as a secondary outcome. A total of six studies comprising 750 patients were included in the present meta-analysis. The neoadjuvant therapy group exhibited significantly superior OS [hazard ratio (HR), 0.39; P
doi_str_mv 10.3892/ol.2025.14868
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11726279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>39807096</sourcerecordid><originalsourceid>FETCH-LOGICAL-c274t-6071c86c4fa44bf7c8a10710e53e8833c5d83a9aff91bf06dc5c4c1ef4e6c0dd3</originalsourceid><addsrcrecordid>eNpVUctOwzAQtBCIVqVHrsg_kGLn4ThcUFWVh1SJC5ytjWOTVE4cOW5QbvwCv8iXkFKoYC-72p2Z1e4gdEnJIuJZeG3NIiRhsqAxZ_wETWmahQElPDw91mk8QfOu25IxEkY5Z-doEmWcpCRjU9Svta4kyAFDU-AOtPIDtho3ykKx3fXQeOxL5aAdsLYOl6oFb6UyZmfAYQlOVo2tAb9VvsStdR4M7lXVjCxn69x2VXeDl7hWHj7fP6ABM4ytC3SmwXRq_pNn6OVu_bx6CDZP94-r5SaQYRr7gJGUSs5krCGOc51KDuNFlKgkUpxHkUwKHkEGWmc014QVMpGxpErHiklSFNEM3R50211eq0KqxjswonVVDW4QFirxf9JUpXi1vaA0DVmYZqNCcFCQznadU_pIpkTsTRDWiL0J4tuEEX_1d-MR_fvy6AvQC4f2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis</title><source>PubMed Central</source><creator>Xuan, Wangyi ; Zhang, Xiaoming ; Fang, Yingying ; Zhang, Yueming ; Xiang, Zhiyi ; Yu, Yifei ; Wu, Qingping ; Zhang, Xingfen</creator><creatorcontrib>Xuan, Wangyi ; Zhang, Xiaoming ; Fang, Yingying ; Zhang, Yueming ; Xiang, Zhiyi ; Yu, Yifei ; Wu, Qingping ; Zhang, Xingfen</creatorcontrib><description>Hepatocellular carcinoma (HCC) with coexisting portal vein tumor thrombus (PVTT) is associated with poor patient outcomes. The efficacy and safety of neoadjuvant therapy in patients with HCC with PVTT remain a subject of debate. In the present study, a comprehensive search of electronic databases, including PubMed, Web of Science, Embase and the Cochrane Library, was conducted to identify studies evaluating the outcomes of neoadjuvant therapy in patients with HCC and PVTT. The primary outcomes assessed were overall survival (OS) and relapse-free survival (RFS), with complication rates as a secondary outcome. A total of six studies comprising 750 patients were included in the present meta-analysis. The neoadjuvant therapy group exhibited significantly superior OS [hazard ratio (HR), 0.39; P&lt;0.001] and RFS (HR, 0.31; P&lt;0.001) compared with the primary hepatectomy control group. Compared with the control group, neoadjuvant radiotherapy improved OS (HR, 0.34; P&lt;0.001) and RFS (HR, 0.24; P=0.004). While the neoadjuvant intervention subgroup exhibited an improved OS compared with controls (HR, 0.37; P=0.001), no significant difference in RFS was observed (HR, 0.11; P=0.095). Geographical analysis revealed that the Chinese subgroup demonstrated a significantly improved OS and RFS (HR, 0.41 for both; P&lt;0.001), compared with the control group. However, the Japanese and Korean subgroups showed no improvement in OS (HR, 0.25; P=0.057) compared with the control group, and the results did not reach statistical significance. There were no significant differences between the groups in terms of blood transfusion, blood loss, operation time, bile leakage, ascites, peritoneal infection, postoperative bleeding, complications or mortality (all P&gt;0.05). Overall, neoadjuvant therapy significantly improved survival outcomes in patients with HCC and PVTT without increasing complication rates, supporting its efficacy and manageable safety profile.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2025.14868</identifier><identifier>PMID: 39807096</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><ispartof>Oncology letters, 2025-03, Vol.29 (3), p.122, Article 122</ispartof><rights>Copyright: © 2025 Xuan et al.</rights><rights>Copyright: © 2025 Xuan et al. 2025</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c274t-6071c86c4fa44bf7c8a10710e53e8833c5d83a9aff91bf06dc5c4c1ef4e6c0dd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726279/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726279/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39807096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xuan, Wangyi</creatorcontrib><creatorcontrib>Zhang, Xiaoming</creatorcontrib><creatorcontrib>Fang, Yingying</creatorcontrib><creatorcontrib>Zhang, Yueming</creatorcontrib><creatorcontrib>Xiang, Zhiyi</creatorcontrib><creatorcontrib>Yu, Yifei</creatorcontrib><creatorcontrib>Wu, Qingping</creatorcontrib><creatorcontrib>Zhang, Xingfen</creatorcontrib><title>Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Hepatocellular carcinoma (HCC) with coexisting portal vein tumor thrombus (PVTT) is associated with poor patient outcomes. The efficacy and safety of neoadjuvant therapy in patients with HCC with PVTT remain a subject of debate. In the present study, a comprehensive search of electronic databases, including PubMed, Web of Science, Embase and the Cochrane Library, was conducted to identify studies evaluating the outcomes of neoadjuvant therapy in patients with HCC and PVTT. The primary outcomes assessed were overall survival (OS) and relapse-free survival (RFS), with complication rates as a secondary outcome. A total of six studies comprising 750 patients were included in the present meta-analysis. The neoadjuvant therapy group exhibited significantly superior OS [hazard ratio (HR), 0.39; P&lt;0.001] and RFS (HR, 0.31; P&lt;0.001) compared with the primary hepatectomy control group. Compared with the control group, neoadjuvant radiotherapy improved OS (HR, 0.34; P&lt;0.001) and RFS (HR, 0.24; P=0.004). While the neoadjuvant intervention subgroup exhibited an improved OS compared with controls (HR, 0.37; P=0.001), no significant difference in RFS was observed (HR, 0.11; P=0.095). Geographical analysis revealed that the Chinese subgroup demonstrated a significantly improved OS and RFS (HR, 0.41 for both; P&lt;0.001), compared with the control group. However, the Japanese and Korean subgroups showed no improvement in OS (HR, 0.25; P=0.057) compared with the control group, and the results did not reach statistical significance. There were no significant differences between the groups in terms of blood transfusion, blood loss, operation time, bile leakage, ascites, peritoneal infection, postoperative bleeding, complications or mortality (all P&gt;0.05). Overall, neoadjuvant therapy significantly improved survival outcomes in patients with HCC and PVTT without increasing complication rates, supporting its efficacy and manageable safety profile.</description><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNpVUctOwzAQtBCIVqVHrsg_kGLn4ThcUFWVh1SJC5ytjWOTVE4cOW5QbvwCv8iXkFKoYC-72p2Z1e4gdEnJIuJZeG3NIiRhsqAxZ_wETWmahQElPDw91mk8QfOu25IxEkY5Z-doEmWcpCRjU9Svta4kyAFDU-AOtPIDtho3ykKx3fXQeOxL5aAdsLYOl6oFb6UyZmfAYQlOVo2tAb9VvsStdR4M7lXVjCxn69x2VXeDl7hWHj7fP6ABM4ytC3SmwXRq_pNn6OVu_bx6CDZP94-r5SaQYRr7gJGUSs5krCGOc51KDuNFlKgkUpxHkUwKHkEGWmc014QVMpGxpErHiklSFNEM3R50211eq0KqxjswonVVDW4QFirxf9JUpXi1vaA0DVmYZqNCcFCQznadU_pIpkTsTRDWiL0J4tuEEX_1d-MR_fvy6AvQC4f2</recordid><startdate>20250301</startdate><enddate>20250301</enddate><creator>Xuan, Wangyi</creator><creator>Zhang, Xiaoming</creator><creator>Fang, Yingying</creator><creator>Zhang, Yueming</creator><creator>Xiang, Zhiyi</creator><creator>Yu, Yifei</creator><creator>Wu, Qingping</creator><creator>Zhang, Xingfen</creator><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20250301</creationdate><title>Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis</title><author>Xuan, Wangyi ; Zhang, Xiaoming ; Fang, Yingying ; Zhang, Yueming ; Xiang, Zhiyi ; Yu, Yifei ; Wu, Qingping ; Zhang, Xingfen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c274t-6071c86c4fa44bf7c8a10710e53e8833c5d83a9aff91bf06dc5c4c1ef4e6c0dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Xuan, Wangyi</creatorcontrib><creatorcontrib>Zhang, Xiaoming</creatorcontrib><creatorcontrib>Fang, Yingying</creatorcontrib><creatorcontrib>Zhang, Yueming</creatorcontrib><creatorcontrib>Xiang, Zhiyi</creatorcontrib><creatorcontrib>Yu, Yifei</creatorcontrib><creatorcontrib>Wu, Qingping</creatorcontrib><creatorcontrib>Zhang, Xingfen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xuan, Wangyi</au><au>Zhang, Xiaoming</au><au>Fang, Yingying</au><au>Zhang, Yueming</au><au>Xiang, Zhiyi</au><au>Yu, Yifei</au><au>Wu, Qingping</au><au>Zhang, Xingfen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2025-03-01</date><risdate>2025</risdate><volume>29</volume><issue>3</issue><spage>122</spage><pages>122-</pages><artnum>122</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Hepatocellular carcinoma (HCC) with coexisting portal vein tumor thrombus (PVTT) is associated with poor patient outcomes. The efficacy and safety of neoadjuvant therapy in patients with HCC with PVTT remain a subject of debate. In the present study, a comprehensive search of electronic databases, including PubMed, Web of Science, Embase and the Cochrane Library, was conducted to identify studies evaluating the outcomes of neoadjuvant therapy in patients with HCC and PVTT. The primary outcomes assessed were overall survival (OS) and relapse-free survival (RFS), with complication rates as a secondary outcome. A total of six studies comprising 750 patients were included in the present meta-analysis. The neoadjuvant therapy group exhibited significantly superior OS [hazard ratio (HR), 0.39; P&lt;0.001] and RFS (HR, 0.31; P&lt;0.001) compared with the primary hepatectomy control group. Compared with the control group, neoadjuvant radiotherapy improved OS (HR, 0.34; P&lt;0.001) and RFS (HR, 0.24; P=0.004). While the neoadjuvant intervention subgroup exhibited an improved OS compared with controls (HR, 0.37; P=0.001), no significant difference in RFS was observed (HR, 0.11; P=0.095). Geographical analysis revealed that the Chinese subgroup demonstrated a significantly improved OS and RFS (HR, 0.41 for both; P&lt;0.001), compared with the control group. However, the Japanese and Korean subgroups showed no improvement in OS (HR, 0.25; P=0.057) compared with the control group, and the results did not reach statistical significance. There were no significant differences between the groups in terms of blood transfusion, blood loss, operation time, bile leakage, ascites, peritoneal infection, postoperative bleeding, complications or mortality (all P&gt;0.05). Overall, neoadjuvant therapy significantly improved survival outcomes in patients with HCC and PVTT without increasing complication rates, supporting its efficacy and manageable safety profile.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>39807096</pmid><doi>10.3892/ol.2025.14868</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-1074
ispartof Oncology letters, 2025-03, Vol.29 (3), p.122, Article 122
issn 1792-1074
1792-1082
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11726279
source PubMed Central
title Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A03%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20neoadjuvant%20therapy%20for%20hepatocellular%20carcinoma%20with%20portal%20vein%20thrombosis:%20A%20meta%E2%80%91analysis&rft.jtitle=Oncology%20letters&rft.au=Xuan,%20Wangyi&rft.date=2025-03-01&rft.volume=29&rft.issue=3&rft.spage=122&rft.pages=122-&rft.artnum=122&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2025.14868&rft_dat=%3Cpubmed_cross%3E39807096%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/39807096&rfr_iscdi=true